Reports Q4 revenue $2.59M, consensus $11.55M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VERU:
- Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
- Veru Tanks After FDA Snub For COVID-19 Therapy
- Veru price target lowered to $21 from $24 at H.C. Wainwright
- Veru announces update on FDA AdCom meeting on Sabizabulin as COVID treatment
- Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Questions or Comments about the article? Write to editor@tipranks.com